Table 2.

The univariate Cox proportional hazard regression model of TNBC patients (WCH; N = 608).

	5-year iDFS		5-year overall survival		5-year LRFS
Variables	HR(95% CI)	P-value	HR(95% CI)	P-value	HR(95% CI)	P-value
Age (y)
≤ 40	Reference		Reference		Reference
41–50	0.86(0.45–1.66)	0.661	0.73(0.35–1.55)	0.418	0.33(0.08–1.37)	0.126
51–60	0.72(0.39–1.34)	0.303	0.61(0.30–1.24)	0.173	0.62(0.21–1.86)	0.395
≥ 60	0.82(0.43–1.55)	0.539	0.71(0.34–1.47)	0.350	0.37(0.10–1.39)	0.142
Grade
II	Reference		Reference		Reference
III	0.73(0.38–1.39)	0.337	0.65(0.30–1.40)	0.274	0.61(0.17–2.15)	0.437
T stage
T1	Reference		Reference		Reference
T2–4	1.88(1.27–2.78)	0.002**	2.07(1.25–3.42)	0.004**	2.38(0.84–6.80)	0.104
N stage
N0	Reference		Reference		Reference
N1–3	2.36(1.72–3.24)	<0.001***	3.00(1.99–4.52)	<0.001***	3.04(1.38–6.72)	0.006**
PMRT
No	Reference		Reference		Reference
Yes	1.23(0.81–1.86)	0.324	1.31(0.80–2.14)	0.279	1.18(0.49–2.85)	0.713
Ki–67
≤ 20%	Reference		Reference		Reference
> 20%	0.96(0.54–1.70)	0.891	1.21(0.65–2.26)	0.554	2.21(0.86–5.69)	0.101
Menopause
No	Reference		Reference		Reference
Yes	0.97(0.65–1.46)	0.899	1.08(0.67–1.75)	0.747	1.14(0.48–2.69)	0.762
LVI
No	Reference		Reference		Reference
Yes	1.26(0.80–1.99)	0.323	1.48(0.87–2.52)	0.153	3.47(1.26–9.57)	0.016*
NACT
No	Reference		Reference		Reference
Yes	2.39(1.54–3.72)	<0.001***	3.50(2.13–5.76)	<0.001***	3.50(1.45–8.46)	0.005**
ACT
No	Reference		Reference		–
Yes	1.22(0.17–8.77)	0.841	0.85(0.12–6.12)	0.871	–	–

*iDFS invasive disease-free survival, LRFS local recurrence–free survival, HR hazard ratio, PMRT postmastectomy radiotherapy, LVI lymphovascular invasion, NACT neoadjuvant chemotherapy, ACT adjuvant chemotherapy. ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05.